Last reviewed · How we verify
Respiratory Syncytial Vaccine
Respiratory Syncytial Vaccine is a Biologic drug developed by Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.. It is currently FDA-approved. Also known as: BARS13.
The Respiratory Syncytial Vaccine, developed by Advaccine (Suzhou) Biopharmaceuticals Co., Ltd., is currently marketed but lacks detailed information on its mechanism and primary indication. A key strength of the vaccine is its market presence, with a key composition patent expiring in 2028, which may provide some protection against generic competition. The primary risk is the lack of disclosed revenue data and key trial results, which could affect investor confidence and market adoption.
At a glance
| Generic name | Respiratory Syncytial Vaccine |
|---|---|
| Also known as | BARS13 |
| Sponsor | Advaccine (Suzhou) Biopharmaceuticals Co., Ltd. |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products (PHASE4)
- Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women (PHASE1)
- Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above (PHASE3)
- A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose (PHASE3)
- Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate (PHASE1, PHASE2)
- Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy (PHASE4)
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Respiratory Syncytial Vaccine CI brief — competitive landscape report
- Respiratory Syncytial Vaccine updates RSS · CI watch RSS
- Advaccine (Suzhou) Biopharmaceuticals Co., Ltd. portfolio CI
Frequently asked questions about Respiratory Syncytial Vaccine
What is Respiratory Syncytial Vaccine?
Who makes Respiratory Syncytial Vaccine?
Is Respiratory Syncytial Vaccine also known as anything else?
What development phase is Respiratory Syncytial Vaccine in?
Related
- Manufacturer: Advaccine (Suzhou) Biopharmaceuticals Co., Ltd. — full pipeline
- Also known as: BARS13
- Compare: Respiratory Syncytial Vaccine vs similar drugs
- Pricing: Respiratory Syncytial Vaccine cost, discount & access